PL340711A1 - Derivatives of 5-(2-imidazolinamino)-benzimidazole, their production and application of them as antagonists of alpha-adrenergic receptors of improved metabolic stability - Google Patents

Derivatives of 5-(2-imidazolinamino)-benzimidazole, their production and application of them as antagonists of alpha-adrenergic receptors of improved metabolic stability

Info

Publication number
PL340711A1
PL340711A1 PL98340711A PL34071198A PL340711A1 PL 340711 A1 PL340711 A1 PL 340711A1 PL 98340711 A PL98340711 A PL 98340711A PL 34071198 A PL34071198 A PL 34071198A PL 340711 A1 PL340711 A1 PL 340711A1
Authority
PL
Poland
Prior art keywords
alpha
benzimidazole
imidazolinamino
antagonists
derivatives
Prior art date
Application number
PL98340711A
Other languages
English (en)
Inventor
Thomas Lee Cupps
Sophie Lee Bogdan
Nicholas Nikolaides
Sheri Ann Gilbert
Michael Gazda
Roy Lee Martin Dobson
Charles Andrew Cruze Iii
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PL340711A1 publication Critical patent/PL340711A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL98340711A 1997-11-24 1998-11-20 Derivatives of 5-(2-imidazolinamino)-benzimidazole, their production and application of them as antagonists of alpha-adrenergic receptors of improved metabolic stability PL340711A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6676797P 1997-11-24 1997-11-24
US6670097P 1997-11-25 1997-11-25

Publications (1)

Publication Number Publication Date
PL340711A1 true PL340711A1 (en) 2001-02-26

Family

ID=26747058

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98340711A PL340711A1 (en) 1997-11-24 1998-11-20 Derivatives of 5-(2-imidazolinamino)-benzimidazole, their production and application of them as antagonists of alpha-adrenergic receptors of improved metabolic stability

Country Status (23)

Country Link
US (1) US6486190B1 (enExample)
EP (1) EP1037887B1 (enExample)
JP (1) JP2001524478A (enExample)
KR (1) KR20010032435A (enExample)
CN (1) CN1284073A (enExample)
AT (1) ATE271048T1 (enExample)
BR (1) BR9815017A (enExample)
CA (1) CA2311344C (enExample)
CO (1) CO4970802A1 (enExample)
DE (1) DE69825075T2 (enExample)
ES (1) ES2223143T3 (enExample)
HU (1) HUP0101469A3 (enExample)
IL (1) IL136303A (enExample)
IN (1) IN190809B (enExample)
NO (1) NO20002655L (enExample)
NZ (1) NZ504707A (enExample)
PE (1) PE133699A1 (enExample)
PL (1) PL340711A1 (enExample)
RU (1) RU2193562C2 (enExample)
SK (1) SK7792000A3 (enExample)
TR (1) TR200002242T2 (enExample)
TW (1) TW505642B (enExample)
WO (1) WO1999026942A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081443A1 (en) 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
RU2225401C1 (ru) * 2002-09-16 2004-03-10 Катаев Валерий Алексеевич 5(6)-нитро-1-(1,1-диоксотиетанил-3)-2-хлорбензимидазол, проявляющий биологическую активность
US20040167194A1 (en) * 2003-02-20 2004-08-26 Randall Jared Lynn Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form
US7268255B2 (en) * 2003-02-20 2007-09-11 Lonza Ag Process for the preparation of N-substituted formamides
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
ES2424644T3 (es) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
RU2306137C1 (ru) * 2005-12-28 2007-09-20 Денис Вячеславович Лисицын Средство для профилактики и лечения гриппа
WO2013130577A2 (en) * 2012-02-27 2013-09-06 Eye Therapies, Llc Compositions and methods for the treatment of migraine
US20150133516A1 (en) * 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
KR20180105129A (ko) * 2015-11-30 2018-09-27 노부스 테라퓨틱스, 인크. 이과학적 예방 및 치료를 위한 조성물 및 방법
EA030197B1 (ru) * 2016-03-22 2018-07-31 Общество С Ограниченной Ответственностью "Рубикон" Таблетированная форма противовирусного лекарственного средства
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
EP0025269B1 (en) 1979-08-23 1985-11-13 Beecham Group Plc Anti-diarrhoea veterinary composition
WO1982000824A1 (en) 1980-09-05 1982-03-18 Geissmann F 1h and 2h indazol derivatives and medicaments containing them
FR2638356A1 (fr) 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
TW300219B (enExample) * 1991-09-14 1997-03-11 Hoechst Ag
US5478858A (en) 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor

Also Published As

Publication number Publication date
CN1284073A (zh) 2001-02-14
PE133699A1 (es) 2000-03-05
ES2223143T3 (es) 2005-02-16
CA2311344A1 (en) 1999-06-03
CO4970802A1 (es) 2000-11-07
KR20010032435A (ko) 2001-04-25
BR9815017A (pt) 2001-09-11
CA2311344C (en) 2006-02-07
IN190809B (enExample) 2003-08-23
HUP0101469A3 (en) 2003-01-28
IL136303A (en) 2004-02-08
HUP0101469A2 (hu) 2001-10-28
DE69825075D1 (de) 2004-08-19
DE69825075T2 (de) 2005-08-25
TR200002242T2 (tr) 2000-11-21
EP1037887B1 (en) 2004-07-14
WO1999026942A8 (en) 2000-08-03
ATE271048T1 (de) 2004-07-15
US6486190B1 (en) 2002-11-26
IL136303A0 (en) 2001-05-20
EP1037887A1 (en) 2000-09-27
JP2001524478A (ja) 2001-12-04
NO20002655D0 (no) 2000-05-24
SK7792000A3 (en) 2001-01-18
NO20002655L (no) 2000-07-24
NZ504707A (en) 2002-11-26
WO1999026942A1 (en) 1999-06-03
RU2193562C2 (ru) 2002-11-27
TW505642B (en) 2002-10-11

Similar Documents

Publication Publication Date Title
DK1513826T3 (da) Hidtil ukendte indolylpiperidinderivater som kraftige antihistamin- og antiallergimidler
IL136303A0 (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as alpha -adrenoceptor agonists with improved metabolic stability
BG110227A (en) USE OF MODULATORS OF THE GLUCOCORTICOID RECEPTOR
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
DK0403159T3 (da) Imidazolylalkensyrer
DE69329727D1 (de) Neue imidazol derivate, ihre herstellung und therapeutische verwendung
DE69007740D1 (de) Substituierte 5-[(Tetrazolyl)alkenyl]-Imidazole.
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
ATE177095T1 (de) Substituierte piperidine für die behandlung von allergischen krankheiten
ATE450260T1 (de) Therapeutische zusammensetzungen enthaltend 1,2,3,6-tetrahydropyrimidin-2-one und entsprechende methoden
ATE250577T1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
ATE301651T1 (de) Substituierte benzimidazole
MXPA02001764A (es) Compuestos heteropoliciclicos y su uso como antagonistas de receptor de glutamato metabotropico.
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
DE122008000037I1 (de) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
CA2503767A1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
EP0437103A3 (en) Substituted 5-(alkyl)carboxamide imidazoles
ATE463245T1 (de) Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
MY127120A (en) A1 adenosine receptor antagonists
ATE119524T1 (de) Substituierte n-(imidazolyl)alkyl-alanin- derivate.
FI973283A0 (fi) 5-(4-substituoitu piperidinyyli-1)-3-aryyli-valeriaanahappojohdannaisia takykiniinireseptoriantagonisteina
WO2006041830A3 (en) Cgrp receptor antagonists
TR199500956A2 (tr) Benzimidazol türevleri.
AU5614198A (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
DK1497292T3 (da) Azaindolylpiperidinderivater som antihistamin- og antiallergimidler